← All deals

Reach Neuro, Inc.

Other Health CareNeurotechMedical DevicesStroke Recovery
πŸ“ Pittsburgh, PA, United Statesβ€’ Founded 2021
StreetZero Signal 62
Be the first to signal interest

About Reach Neuro, Inc.

Reach Neuro, Inc. was founded in 2021 as a spinout from the University of Pittsburgh and Carnegie Mellon University. The company develops the Avantis device, which pairs approved spinal cord stimulators with nerve-to-muscle mapping to restore arm and hand function in chronic stroke patients with upper limb deficits. It has achieved FDA Breakthrough Device designation, completed a seven-patient feasibility trial, and is conducting a 10-patient pilot study. The technology is being tested in an NIH-funded clinical trial in collaboration with UPMC.

LATEST FUNDINGPrivate Placement
$2.0M
Announced 2026-11-17
TOTAL RAISED$11M
πŸ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Reach Neuro, Inc..

Free plan includes 3 full deal profiles every month.

Key highlights

  • Received FDA Breakthrough Device designation for its spinal cord stimulation technology.
  • Founded in 2021 as a University of Pittsburgh and Carnegie Mellon University spinout.
  • Completed feasibility trial showing grip strength improvements of 40% and 108% in initial participants.
  • Published results in Nature Medicine and is conducting an NIH-funded pilot study at UPMC.
  • Raised approximately $11 million total including over $8 million in non-dilutive funding.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account